Sulphated polysaccharides: new insight in the prevention of cyclosporine A-induced glomerular injury.
The scope of the current study was to examine the possible effects of sulphated polysaccharides against cyclosporine A-induced glomerular injury. Nephrotoxicity induced by cyclosporine A continues to be a major problem despite its potent immunosuppressive action. Adult male albino rats of Wistar strain were categorized into four groups. Two groups (II and IV) were administered cyclosporine A (25 mg/kg body weight, orally) for 21 days, in which Group IV rats were also treated simultaneously with sulphated polysaccharides (5 mg/kg body weight, subcutaneously) for the same period. A significant loss in body weight was noted in the cyclosporine A-induced rats. Renal damage was assessed in terms of decreased creatinine clearance and increased activity of lysosomal enzymes. The levels of glycoproteins were found to be decreased in the renal tissue, and a noticeable rise in glycosaminoglycanuria coupled with marked proteinuria was more prominent in the cyclosporine A-induced animals. Furthermore, the extent of kidney damage was assessed by histopathological findings. Toxic manifestations were also confirmed by transmission electron microscopic studies. These morphological abnormalities and other alterations in the renal tissue were significantly offset by sulphated polysaccharides supplementation. These findings underline that restoration of normal cells accredits sulphated polysaccharides, from Sargassum wightii, with nephroprotective role, against cyclosporine A-induced renal injury.
Josephine
Anthony
A
Department of Medical Biochemistry, Dr. A.L.M. Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, India.
Veena
Coothan Kandaswamy
CK
Amudha
Ganapathy
G
Preetha
Sreenivasan P
SP
Sundarapandian
Rajaguru
R
Varalakshmi
Palaninathan
P
D000818:Animals; D001835:Body Weight; D016572:Cyclosporine / Q000009:adverse effects*; D006867:Hydrolases / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000473:pathology; D008297:Male; D011134:Polysaccharides / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D044647:Sargassum
D007166:Immunosuppressive Agents; D011134:Polysaccharides; D016572:Cyclosporine; D006867:Hydrolases